RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS

Clinical trials for RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS explained in plain language.

Never miss a new study

Get alerted when new RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS trials appear

Sign up with your email to follow new studies for RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

Could a diabetes drug shield kidneys from autoimmune attack?

Disease control Recruiting now

This trial investigates whether pioglitazone, a drug used for diabetes, can help protect the kidneys in people with ANCA-associated vasculitis—a rare autoimmune disease that causes inflammation of blood vessels, often damaging the kidneys. Participants receive either pioglitazone…

Matched conditions: RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS

Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control

Last updated Jul 01, 2026 23:00 UTC

RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS

Get alerted when new RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS trials appear

Could a diabetes drug shield kidneys from autoimmune attack?